RET and multiple endocrine neoplasia type 2A: Hadoux et al. generated a patient-derived iPSCs carrying the RET mutation along with the CRISPR/Cas9-corrected isogenic control to unravel the molecular mechanisms underlying the multiple endocrine neoplasia type 2A [40].